MRI scans of patients show patients with Alzheimers disease. (Credit: Atthapon Raksthaput/Shutterstock) Scientists are still unraveling whyAlzheimers disease affects men and women disproportionately. Out of the 5 million Americans who have it, about 64 percent are women. Continue reading →

Actress Kate Walsh wants to shatter the hushed whispers surrounding menopause. Its part of her effort to bring more awareness so that women can stop suffering in silence Continue reading →

he Global report entails the overall and all-encompassing study of the "Hormone Replacement Therapy Market" with all its relevant factors that might have an influence on the growth of the market. This report is rooted in the methodical quantitative and qualitative evaluation of the global Hormone Replacement Therapy market Continue reading →

ALZHEIMERS affects thousands of people in Ireland and almost everybody has heard of it, but this debilitating and complex condition is still often misunderstood. Classed as a neurological disorder, it causes memory loss and cognitive decline, which usually starts slowly and gradually worsens over time Continue reading →

A transgender man can sue a Catholic hospital over a last-minute hysterectomy cancellation, the 1st District Court of Appeal in San Francisco ruled, the Sacramento Bee reported. Evan Minton's procedure was canceled after the patient told a nurse of being transgender, the paper said, citing the lawsuit. Continue reading →

BARCELONA, Spain, Sept. 27, 2019 /PRNewswire/ --The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated, longer-term results from the pivotal Phase 3 SPARTAN study following a second interim analysis. Treatment with ERLEADA (apalutamide) plus androgen deprivation therapy (ADT) resulted in a 25 percent reduction in the risk of death compared with placebo plus ADT in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1 The updated findings showed overall survival (OS) results supported the first interim analysis, despite a crossover of patients receiving placebo to the ERLEADA treatment group.1Results were presented in an oral session at the 2019 European Society for Medical Oncology (ESMO) Annual Congress (abstract #843O), and simultaneously published in Annals of Oncology Continue reading →

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive data from the Phase III IMpower110 study evaluating Tecentriq (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT). The study met its primary endpoint in an interim analysis showing that Tecentriq monotherapy improved overall survival (OS) by 7.1 months compared with chemotherapy alone (median OS=20.2 versus 13.1 months; hazard ratio [HR]=0.595, 95% CI: 0.3980.890; p=0.0106) in people with high PD-L1 expression (TC3/IC3-WT). Encouraging OS (18.2 versus 14.9 months; HR=0.717, 95% CI: 0.5200.989) was also observed in people with medium levels of PD-L1 expression (TC2/3 or IC2/3-WT), however these data did not reach statistical significance at this interim analysis. Continue reading →

A transgender man desperate to have his breasts removed says he "can't wait two and a half years" for an NHS spot. Jesse Churchill, 24, came out as non-binary transmasculine - a person who was assigned female at birth, but who identifies with masculinity to a greater extent than with femininity - in 2017 Continue reading →